Advertisement

Picture Berlin Partner Join Cluster HealthCapital Berlin Brandenburg 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3953 | Ordered by Date (descending)
1 2 3 ... 38 39 40  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Lunaphore–Norgine: credit, 202303– venture debt €10m from Norgine Ventures 2023-03-23
Lunaphore–SEVERAL: investment, 202303 financing round Series D first closing approx CHF30m led by EGSB 2023-03-23
Mbiomics–Bavaria (govt): investment, 202303 financing round Series A first closing totalling €13m incl co-investor Bayern Kapital 2023-03-23
Mbiomics–High-Tech Gründerfonds: investment, 202303 financing round Series A first closing totalling €13m incl co-investor HTGF 2023-03-23
Mbiomics–MIG Fonds: investment, 202303 financing round Series A first closing totalling €13m incl lead investor MIG Capital 2023-03-23
Mbiomics–OTHER: investment, 202303 financing round Series A first closing totalling €13m incl pool of private seed investors 2023-03-23
Mbiomics–SEVERAL: investment, 202303 financing round Series A first closing €13m led by MIG Capital 2023-03-23
Lilly–Roche: Alzheimer blood test, 202303– collab development of Elecsys Amyloid Plasma Panel for early detection of Alzeimer’s diseasse 2023-03-22
BioNTech–OncoC4: antibody cancer drug, 202303– license ww excl + co-developm incl $200m upfront of anti-CTLA-4 mAb ONC-392 2023-03-20
Aldena Therapeutics–Medicxi: investment, 202303 Aldena emerges with $30m investment from co-founder Medicxi 2023-03-16
Lino Biotech–Miltenyi Biotec: investment, 202303 acquisition €na of Lino Biotech by Miltenyi Biotec 2023-03-16
Seamless Therapeutics–Forbion: investment, 202303 seed financing round totalling €7.9m incl co-lead investor Forbion 2023-03-16
Seamless Therapeutics–SEVERAL: investment, 202303 seed financing round €7.9m led by Wellington Partners + Forbion 2023-03-16
Seamless Therapeutics–Trophic Communications: public relations, 202303 service existent by Trophic 2023-03-16
Seamless Therapeutics–Wellington Partners: investment, 202303 seed financing round totalling €7.9m incl co-lead investor Wellington Partners 2023-03-16
Turnstone Biologics–Scailyte: biomarker discovery, 202303– collab biomarker discovery for TIL therapy using ScaiVision platform 2023-03-16
Mediar Therapeutics–Novartis: investment, 202303c financing round Series A totalling $85m incl co-lead investor Novartis Venture Fund 2023-03-15
Mediar Therapeutics–SEVERAL: investment, 202303c financing round Series A $85m co-led by NVF + Sofinnova Partners 2023-03-15
Iktos–Debiopharm: investment, 202303 financing round Series A totalling €15.5m incl new + co-lead investor Debiopharm Innovation Fund 2023-03-09
Iktos–Merck (DE): investment, 202303 financing round Series A totalling €15.5m incl new + co-lead investor M Ventures 2023-03-09
Iktos–Omnes Capital: investment, 202303 financing round Series A totalling €15.5m incl co-investor Omnes Capital 2023-03-09
Iktos–SEVERAL: investment, 202303 financing round Series A €15.5m co-led by M Ventures + Debiopharm Innovation Fund 2023-03-09
Cellbox Solutions–SEVERAL: investment, 202303 financing round Series A1 €6.5m led by CK Ventures 2023-03-07
Noema Pharma–SEVERAL: investment, 202303 financing round Series B CHF103m ($12m) co-led by Forbion + Jeito Capital 2023-03-07
Calibre Scientific–Eppendorf: micromanipulation products, 202303 acquistion of micro manipulation product portfolio of Eppendorf by Calibre Scientific 2023-03-06
Confo Therapeutics–Trophic Communications: public relations, 202303 service existent by Trophic 2023-03-02
Simulands–SHS Capital: investment, 202303 investment €10m in Simulands by SHS 2023-03-02
BioNTech–Weizmann Institute: mRNA technology, 202303– collab research in Israel with new BioNTech nRNA Excellence Center MOU 2023-03-01
Bico–ABB: laboratory automation equipment, 202302 collab product integration Nucleus Automation Ecosystem + sciFLEXARRAYER of Scienion + ABB Robotics 2023-02-27
VisionHealth–Bruchmann Group: investment, 202302 financing round pre-Series A totalling €3m incl new + lead investor DB Speciality Invest 2023-02-27
VisionHealth–SEVERAL: investment, 202302 financing round pre-Series A €3m led by DB Speciality Invest 2023-02-27
Resalis Therapeutics–Trophic Communications: public relations, 202302 service existent by Trophic 2023-02-22
Lift BioSciences–Resonac: biologics contract manufacturing, 202302– collab developm + manufacturing of N-LIfT for clinical trials by Minaris RM 2023-02-16
Hexagon Bio–Nextech: investment, 202302 financing round Series B totalling $77.3m incl existing investor Nextech 2023-02-13
Hexagon Bio–SEVERAL: investment, 202302 financing round Series B $77.3m from existing + new investors 2023-02-13
Life Science Valley–Lower Saxony (govt): investment, 202302 fund launch with total of €12m incl €6m from NBank 2023-02-13
Life Science Valley–Sartorius: investment, 202302 fund launch with total of €12m incl €6m from Sartorius + Univ Medical Center Göttingen combined 2023-02-13
Life Science Valley–SEVERAL: investment, 202302 fund launch with €12m incl €6m from Niedersachsen + remainder from Sartorius + Univ Göttingen 2023-02-13
Life Science Valley–Univ Göttingen: investment, 202302 fund launch with total of €12m incl €6m from Univ Medical Center Göttingen + Sartorius combined 2023-02-13
AMSilk–BRAIN Biotech: biomaterials, 202302– strategic collaboration development of high-performance bio-based protein fibers 2023-02-08
APK–SEVERAL: investment, 202302– financing round €130m incl minority investments from LyondellBasell + KIRKBI A/S 2023-02-08
BrainRepair–OTHER: investment, 202302 investment €50m for 20% of shares of BrainRepair UG by London-based group 2023-02-08
CureVac–SEVERAL: investment, 202302 public offering $250m+$37.5m with 27m+4.05m common shares at $9.25/share 2023-02-06
JnJ–Evotec: cancer immunotherapy, 202301– strategic collab + license agreem developm first-in-class targeted immune-based cancer therapies 2023-01-26
Refined Laser Systems–Apex Ventures: investment, 202301 seed financing round totalling €2.7m incl co-lead investor Apex Medical Fund 2023-01-26
Refined Laser Systems–High-Tech Gründerfonds: investment, 202301 seed financing round totalling €2.7m incl co-lead investor HTGF 2023-01-26
Refined Laser Systems–North Rhine-Westphalia (govt): investment, 202301 seed financing round totalling €2.7m incl co-investor NRW.Bank 2023-01-26
Refined Laser Systems–Onsight Ventures: investment, 202301 seed financing round totalling €2.7m incl co-investor Onsight Ventures 2023-01-26
Refined Laser Systems–Papst: investment, 202301 seed financing round totalling €2.7m incl co-investor Papst Venture Capital 2023-01-26
Refined Laser Systems–PERSON: investment, 202301 seed financing round totalling €2.7m incl private investors T Merk + HM Hauser + W Falkenstein 2023-01-26
Refined Laser Systems–SEVERAL: investment, 202301 seed financing round €2.7m led by HTGF + Apex Ventures 2023-01-26
Novartis–Astellas: micafungin, 202110– acquisition of ww product rights to Mycamine/Funguard by Sandoz from Astellas SIGNED 2023-01-24
Agilent–Plasmion: ionisation technology, 202301– collab co-marketing of SICRIT ion source with Agilent Ultivo LC/TQ + LC/MSD iQ MS systems 2023-01-18
Blackford Analysis–Bayer: investment, 202301–202302 acquisition by Bayer 2023-01-18
Siemens–ASG Superconductors: magnetic resonance imaging, 202301– collab integration of ASG MRI magnets >7T in Siemens Healthineers UFH MRI systems 2023-01-18
Bayer–Alphabet: cloud computing services, 202301– collab using Google Cloud TPUs for quantum chemitry calculations in drug discovery 2023-01-11
Boehringer–Minapharm: rec protein production technology, 202301– collab non-excl €na of ProBioGen + Boehringer on DirectedLuck transposase technology 2023-01-10
NextPoint Therapeutics–Bayer: investment, 202301 financing round Series B totalling $80m incl new + co-lead investor Leaps by Bayer 2023-01-10
NextPoint Therapeutics–Sanofi: investment, 202301 financing round Series B totalling $80m incl new + co-lead investor Sanofi Ventures 2023-01-10
NextPoint Therapeutics–SEVERAL: investment, 202301 financing round Series B $80m co-led by Leaps by Bayer + Sanofi Ventures 2023-01-10
Boehringer–3T Biosciences: cancer immunotherapies, 202301– strategic collab + license agreem RnD of cancer therapies using 3T-TRACE discovery platform 2023-01-09
Proteros–Inflexion: investment, 202301– minority investment by Inflexion with founder + CEO Torsten Neuefeind remaing majority shareholder + CEO 2023-01-09
Verogen–Qiagen: investment, 202301c full acquisition of Verogen for $150m in cash 2023-01-09
Acquifer Imaging–Bruker: investment, 202301 acquisition €na of Acquifer Imaging Gmbh + subsidiary Deltabyte GmbH by Bruker 2023-01-05
BioVersys–AMR Action Fund: investment, 202301 financing round Series C extension with CHF8.2m? from AMR AF bringing total Series C to CHF32.6m 2023-01-05
Biognosys–Bruker: investment, 202301 acquisition €na of majority share in Biognosys by Bruker 2023-01-04
Seamless Therapeutics–Germany (govt): grant, 202301–202512 GO-Bio Phase II grant €3.9m from BMBF 2023-01-01
Selfapy–Berlin (govt): investment, 202212 financing round totalling €7m incl existing + co-investor IBB Ventures 2022-12-23
Selfapy–High-Tech Gründerfonds: investment, 202212 financing round totalling €7m incl existing + co-investor HTGF 2022-12-23
Selfapy–Medice: investment, 202212 financing round totalling €7m incl new + lead investor Medice Arzneimittel 2022-12-23
Selfapy–SEVERAL: investment, 202212 financing round €7m led by new investor Medice Arzneimittel plus all existing investors 2022-12-23
Selfapy–SHS: investment, 202212 financing round totalling €7m incl existing + co-investor SHS 2022-12-23
Selfapy–Think.Health: investment, 202212 financing round totalling €7m incl existing + co-investor Think.Health Ventures 2022-12-23
Merck (DE)–Mersana: ADC technology, 202212– collab €30m upfront + $800m milestones + royalties using Immunosynthen platform for STING-agonist ADCs 2022-12-22
Numares–EU (govt): credit, 202212– quasi-equity venture debt financing up to €20m from EIB 2022-12-20
Numares–SEVERAL: investment, 202212 financing round €20m from existing investors 2022-12-20
Boehringer–Click Therapeutics: digital therapeutics, 202212– collab expansion to develop 2nd DTx for schizophrenia up to $460m + royalties 2022-12-19
S-Biomedic–Beiersdorf: investment, 202212 acquisition €na of majority share in S-Biomedic NV by Beiersdorf AG 2022-12-16
Minervax–Bellevue: investment, 202212 financing round totalling €22m incl new + co-lead investor Pureos Bioventures 2022-12-15
Minervax–Novo Group: investment, 202212 financing round totalling €22m incl exisiting + co-investor Novo REPAIR Impact Fund 2022-12-15
Minervax–SEVERAL: investment, 202212 financing round €22m co-led by Trill Impact Ventures + Pureos Bioventures 2022-12-15
Minervax–Sunstone Life Science: investment, 202212 financing round totalling €22m incl exisiting + co-investor Sunstone Life Science Ventures 2022-12-15
Minervax–Wellington Partners: investment, 202212 financing round totalling €22m incl exisiting + co-investor Wellington Partners 2022-12-15
Storm Therapeutics–Merck (DE): investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor M Ventures 2022-12-14
Storm Therapeutics–SEVERAL: investment, 202212 financing round Series B $30m led by M Ventures + Pfizer Ventures + Taiho Ventures + CIC 2022-12-14
Merck (DE)–Synplogen: viral vectors, 202212– collab MoU integration of offerings for viral vector dev + production for gene therapies in Japan 2022-12-13
Icosagen–Genedata: bioinformatics, 202212– supply deployment of GeneData Biologics by Icosagen 2022-12-12
Bico–Sartorius: investment, 202212– directed share issue SEK487m (€45m) to existing investor Sartorius resulting 10.1% share + 8.5% of voting rights 2022-12-08
Ryvu Therapeutics–Augebit FIZ: investment, 202212 public offering totalling PLN250.3m incl PLN13m from Augebit FIZ fund 2022-12-08
Ryvu Therapeutics–Leukemia & Lymphoma Society: investment, 202212 public offering totalling PLN250.3m incl PLN4.5m from LLS TAP 2022-12-08
Ryvu Therapeutics–PERSON: investment, 202212 public offering totalling PLN250.3m incl PLN10m from co-founder + CEO + largest owner P Przewiezlikowski 2022-12-08
Ryvu Therapeutics–SEVERAL: investment, 202212 public offering PLN250.3m of 4.8m Series J common shares led by BioNTech 2022-12-08
Sartorius–Bico: laboratory equipment, 202212– collab RnD 3D cell printing technologies + digital soluitons for cell line development workflows 2022-12-08
Sartorius–Bico: laboratory equipment, 202212– distribution of Bico products in APAC region by Sartorius 2022-12-08
Erbi Biosytems–Merck (DE): investment, 202212 acquisition €na of Erbi Biosystems by Merck 2022-12-01
BioNTech–Ryvu Therapeutics: small molecule immuno modulators, 202211– collab + license €20m upfront + research funding + milestones + royalties 2022-11-30
Ryvu Therapeutics–BioNTech: investment, 202212 public offering totalling PLN250.3m incl PLN94m (€20m) from lead investor BioNTech related to collab 2022-11-30
Cajal Neuroscience–Evotec: investment, 202211 financing round Series A totalling $96m incl existing + co-investor Evotec 2022-11-29
Cajal Neuroscience–SEVERAL: investment, 202211 financing round Series A $96m led by The Column Group + Lux Capital 2022-11-29
Rgenta Therapeutics–SEVERAL: investment, 202211 financing round Series A $52m led by AZ-CICC Healthcare Investment Fund 2022-11-29
1 2 3 ... 38 39 40  next pagenext page



Advertisement

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Bio-Europe Spring 2023 Basel 650x300px

» top